Loading…

Freenome, Inc.FRNMCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Early cancer-detection company developing blood-based, AI-driven screening tests, starting with colorectal cancer.

≈ An AI-driven, blood-test rival to Exact Sciences' Cologuard
Mkt cap
$1.08B
US dollars, full cap
Free float
71%
of shares outstanding
$/day
$9.04M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+13.1 pp
WACC 7.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · USD$9.73
1D-0.9%
1W-15.8%
1M-30.8%
3M-28.0%
6Mn/a
YTDn/a
1Yn/a
ATR %9.6%
52w lowhigh44.4% off high

What Freenome does

Early cancer-detection company developing blood-based, AI-driven screening tests, starting with colorectal cancer.

In one line: An AI-driven, blood-test rival to Exact Sciences' Cologuard.

Products and services

  • Preempt CRC (colorectal cancer blood test)
  • Multi-cancer early detection pipeline

Customers

  • Primary care physicians
  • Screening-eligible adults

Where it sits in the supply chain

  • Diagnostics
  • Liquid biopsy / multi-cancer screening
  • Blood-based cancer screening tests

What could go right

  • Colorectal cancer screening compliance gap
  • Blood-test convenience vs colonoscopy/stool tests

What could go wrong

  • Reimbursement/payer coverage uncertainty
  • Competitive liquid-biopsy landscape

Moat: narrow (data, IP / patents). AI/multiomics platform trained on large blood-sample datasets aims to detect early-stage cancer signals.

Headquarters: South San Francisco, California · Founded: 2013 · Employees: 3

Named competitors

Freenome at a glance

Size Freenome (FRNM) is a United States Health Care company (Medical Specialties) with a market value of $1.08B, the 2174th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.73 on 18 Nov 2026.

Growth The operating margin is 36.2% (peer median 11.6%).

Valuation It trades at 4.7× enterprise value to sales against a peer median of 4.0× (9th most expensive of 20).

Capital Return on invested capital runs 13.1 points above its cost of capital (7.6% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Freenome financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024
Revenue$183M$0$0
Revenue growth———
Gross profit$177M$0$0
EBITDA$72.5M-$2.98M-$494,000
Net income$59.2M$837,468$1.91M
Free cash flown/a-$864,650-$713,260
Capital expendituren/a$0$0
Total debt$202M$0$0

Quarterly statements and history in the cockpit →

Freenome competitors and peer comparison

Head to head with its named competitors (FRNM vs GH vs NTRA)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Freenome FRNM$1.08Bn/an/a36%4.7×n/a
Guardant Health GH$19.6B+26%+42%-39%15.9×n/a
Natera NTRA$42.0B+41%+37%-9%14.1×n/a

How Freenome compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Freenome against its 20 peers (data as of 18 Nov 2026)
MeasureFRNMPeer medianRank in peer set
1-month return-30.8%-5.1%2nd lowest of 21
Distance from 52-week high-44.4%-29.4%5th lowest of 21
Operating margin36.2%11.6%2nd highest of 20
EV / Sales4.7×4.0×9th most expensive of 20
ROIC minus cost of capital+13.1 pp+0.3 pp7th highest of 19
EV / EBITDA11.8×8.5×3rd most expensive of 7
Net debt / EBITDA-3.1×1.7×least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Freenome FRNMUnited States$1.08Bn/an/a36%4.7×n/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%4.0×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%1.7×5.9%+3.6%
Alphatec ATECUnited States$1.10B-14%+15%-3%1.9×n/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%6.3×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%85.0×n/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%4.3×n/an/a
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%11.1×18.5%+21.5%
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%5.8×1.7%+9.9%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%2.1×57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%2.7×7.7%+12.1%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%4.7×11.3%-3.5%
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%3.0×n/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%11.1×50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%0.9×-4.0%+3.5%
Amoy Diagnostics 300685.SZChina$1.01B-15%+7%34%4.7×4.9%+10.4%
Edan Instruments 300206.SZChina$1.00B-19%+14%17%2.5×6.9%-2.9%
Ceribell CBLLUnited States$995M+42%+31%-70%8.3×n/an/a
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%1.4×n/an/a
INKON Life Technology 300143.SZChina$985M-23%+22%12%3.1×10.7%+12.9%

Questions

Who are Freenome's main competitors?
Named competitors: Exact Sciences (private or unlisted), Guardant Health (GH), Natera (NTRA). The cockpit's measured peer set (industry) also includes CLASSYS (214150.KS), Integra LifeSciences (IART), Alphatec (ATEC), Mingyue Optical Lens (301101.SZ), Guangzhou Hexin Instrument (688622.SS), SI-BONE (SIBN).
Is Freenome expensive compared with its peers?
On ev / sales it trades at 4.7× against a peer median of 4.0×, 9th most expensive of 20 in its peer set.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.